Navigation Links
ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
Date:10/28/2009

worldwide are over $5 billion. Nevertheless, available anticoagulants are still inconvenient and associated with an increased risk of bleeding. Improved anticoagulants are therefore required. In particular, agents that allow for improved ease of administration (without requirement for daily dosing and frequent dose adjustment) would fill a significant unmet need.

Legal disclaimer

This press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Notes to Editors:

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
2. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
3. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
4. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
5. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
6. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
7. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
8. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
9. Elekta Provides Complete Planning, Treatment and Workflow Solution for Roy and Patricia Disney Family Cancer Center
10. Delcath Systems, Inc. Completes Phase III Study Enrollment
11. Abbott Completes Visiogen Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014  Hill-Rom Holdings, Inc. ... to a management presentation at the Morgan Stanley Global ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://cc.talkpoint.com/morg007/090814a_ac/?entity=26_7CLOGQP ... available one hour after conclusion of the live event ...
(Date:8/27/2014)... , Aug. 27, 2014 Sihuan ... or the "Company"), a leading pharmaceutical company with ... China,s prescription drug market, ... Company and its subsidiaries (collectively the "Group") for ... "Period"). Financial HighlightsFor the Six months ...
(Date:8/27/2014)... Aug. 27, 2014  CVS Caremark (NYSE: ... new clinical affiliation with MedStar Health, a leading health ... and the Washington, DC ... health care services for patients. Through this clinical affiliation, ... clinical support, medication counseling, chronic disease monitoring and wellness ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7CVS Caremark Announces New Clinical Affiliation with MedStar Health 2CVS Caremark Announces New Clinical Affiliation with MedStar Health 3
... PALO ALTO, Calif., Feb. 22, 2011 Telik, Inc. (Nasdaq: ... $0.18 per share, for the three months ended December 31, 2010, ... share, for the comparable period in 2009.  For the year ended ... share, compared with a net loss of $23.7 million, or $0.44 ...
... 2011 drugstore.com, inc. (Nasdaq: DSCM ... clinical skincare, and vision products, today announced that ... upcoming events with the financial community: ... & Telecom Conference Date: February 28, 2011Time: 3:20 ...
Cached Medicine Technology:Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 2Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 3Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 4Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance 5drugstore.com to Present at Upcoming Financial Conferences 2
(Date:8/27/2014)... 27, 2014 Millennium Treatment Group is ... for Florida Mental Health Counselors Association (FMHCA). The addiction ... sponsorship is sure to provide. , FMHCA is an ... Florida’s licensed mental health counselors. The organization was founded ... Association (ACA) and since then, it has served the ...
(Date:8/27/2014)... NY (PRWEB) August 27, 2014 The ... Team ) is holding free events about “ Sexuality ... speaker Liz Treston. These straightforward and entertaining discussions are ... at Bussani Mobility (501 Concord Avenue, Mamaroneck, NY) and ... Central Avenue, Bethpage, NY). , The New York ...
(Date:8/27/2014)... Spring, Md. (PRWEB) August 27, 2014 ... (CHEST) recently released guidelines for the management and ... Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: ... are free to view for clinicians, and provide ... PAH. , The Pulmonary Hypertension Association ...
(Date:8/27/2014)... Dennis Thompson HealthDay Reporter ... has been mugged in a dark alley will likely never ... fear of being attacked. But neuroscientists working with mice ... are linked with positive and negative emotions. And in rodent ... to a memory. In essence, they made once-reluctant mice ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Michigan Head & ... the children of a local elementary school by ensuring they ... Elementary School has year-round attendance, and Michigan Head & Neck ... meet the new school year. , "There are a lot ... is a great way to give back to our community," ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sponsors Florida Mental Health Counselors Association 2Health News:Bussani Mobility Sponsors New York Mobility Club Meetings September 9 & October 7 for People with Disabilities, Sexuality & Intimacy Discussed by Advocate Liz Treston 2Health News:Pulmonary Hypertension Association Endorses CHEST Guidelines for Treatment of Pulmonary Arterial Hypertension in Adults 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Michigan Head & Neck Institute is Conducting Their 2nd Annual School Supplies Drive at Their Facility to Benefit Local Year-Round Elementary School Students 2
... 20 (HealthDay News) -- Most Americans consume too much sodium, ... the amount of dietary salt, according to a new study ... are associated with increased risk of high blood pressure, which ... In general, people aged 2 years and older should limit ...
... 20 (HealthDay News) --,Hospital programs to lessen the overuse ... costs, but too few hospitals have fully implemented such ... -- intended to prevent antibiotic resistance -- for acute ... 2007 by the Infectious Diseases Society of America (IDSA) ...
... UCLA have found a possible explanation for why autistic children ... time, they,ve shown that the connections between brain regions that ... slowly in boys with autism than in non-autistic children. ... journal Human Brain Mapping, senior author Jennifer G. ...
... at NYU Langone Medical Center today announce findings published ... that show for the first time the inhibition of ... oligonucleotides markedly suppress triglyceride levels and cause a sustained ... "The discovery of microRNAs in the last ...
... , THURSDAY, Oct. 20 (HealthDay News) -- The key ... skills and more about controlling negative emotions that make ... suggests. The study found that activation of brain ... math anxiety conquer their fears and succeed in math. ...
... Hospital of Rhode Island has been selected by the National ... Floor Disorders Network (PFDN). Women & Infants is one ... the only one in the Northeast, to work collaboratively to ... floor disorders. Co-principal investigators at Women & Infants are ...
Cached Medicine News:Health News:U.S. Diet Still Has Too Much Salt, CDC Warns 2Health News:Hospital Programs to Reduce Antibiotic Resistance Working: Studies 2Health News:Hospital Programs to Reduce Antibiotic Resistance Working: Studies 3Health News:Autistic brains develop more slowly than healthy brains UCLA researchers say 2Health News:Autistic brains develop more slowly than healthy brains UCLA researchers say 3Health News:Novel therapeutic target identified to decrease triglycerides and increase 'good' cholesterol 2Health News:Afraid to Do the Math? 2
... These Low Contrast Flip charts contain 5 pages ... on each page. Optotype size is 9.5M. Contrast ... These flip charts can be used at several ... the same test. Each offers a different ...
Directional `E' and `C' test....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... high-performance recording unit suitable for a wide ... require up to 16 input channels. Examples ... The unit is capable of recording at ... per second continuously to disk, and is ...
Medicine Products: